Brokerages Set Enfusion, Inc. (NYSE:ENFN) Price Target at $10.50

Shares of Enfusion, Inc. (NYSE:ENFN) have received a consensus recommendation of “Hold” from the six research firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $10.50.

ENFN has been the subject of several research analyst reports. Piper Sandler upped their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. William Blair reiterated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Stifel Nicolaus upped their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th.

Insider Buying and Selling

In related news, COO Neal Pawar sold 21,801 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Oleg Movchan sold 2,771 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares in the company, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 57,367 shares of company stock worth $591,335. 36.44% of the stock is owned by insiders.

Institutional Trading of Enfusion

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new stake in Enfusion during the fourth quarter worth $75,000. Harbor Capital Advisors Inc. raised its position in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after acquiring an additional 1,315 shares in the last quarter. Belvedere Trading LLC bought a new stake in Enfusion during the third quarter worth $114,000. Quantbot Technologies LP bought a new stake in Enfusion during the fourth quarter worth $144,000. Finally, Paloma Partners Management Co bought a new stake in Enfusion during the third quarter worth $157,000. 81.05% of the stock is owned by institutional investors.

Enfusion Stock Down 0.3 %

Enfusion stock opened at $11.06 on Thursday. The stock has a market capitalization of $1.42 billion, a PE ratio of 276.57, a price-to-earnings-growth ratio of 1.83 and a beta of 0.96. Enfusion has a twelve month low of $7.83 and a twelve month high of $11.38. The company has a 50 day moving average of $10.70 and a 200-day moving average of $9.54.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.